Partial
Partially Aligned
Patient Risk:
Medium
Summary
Several claims about Rinvoq’s efficacy/mechanism and patient eligibility are not assessable against the provided label excerpts, and multiple safety/administration-related claims are not supported by (or are inconsistent with) the supplied FDA label sections (notably boxed warnings for non-included products and specific adverse event incidence ranges).
Category Scores
Accurate Statements
The FDA label for RINVOQ/RINVOQ LQ supports warnings/risks for serious infections (including opportunistic infections), increased mortality, malignancies/lymphomas, MACE, and thrombosis (including DVT/PE/arterial thrombosis).
Supported by provided label excerpt mappings: 5.1 and 6.1 (serious infections/opportunistic infections), 5.2 (mortality), 5.3 and 6.1 (malignancy/lymphomas), 5.4 (MACE), 5.5 and 6.1 (thrombosis including DVT/PE/arterial thrombosis).
Rinvoq adds thrombosis and mortality risks as black box warning risks.
Supported in substance (thrombosis 5.5; mortality 5.2). Note: whether these are specifically boxed black-box warnings is not directly supported by the provided excerpts.
Tuberculosis screening is required before starting Rinvoq.
Supported: 5.1 states to evaluate and test for latent and active TB infection prior to administration; patients with latent TB should be treated before initiating; should not be given to patients with active TB.
Patients should avoid live vaccines when taking Rinvoq.
Unsupported Statements
Rinvoq (upadacitinib) treats moderate to severe atopic dermatitis (eczema).
Not supported by the provided FDA label excerpts (only Sections 5.1–5.5 and 6.1 risk content were supplied).
Rinvoq is indicated for adults and children 12 years and older weighing at least 40 kg whose condition did not respond to other systemic treatments.
Not supported by the provided FDA label excerpts.
Rinvoq reduces inflammation by blocking Janus kinase (JAK) enzymes.
Not supported by the provided FDA label excerpts.
Rinvoq treatment leads to clearer skin in patients with atopic dermatitis.
Not supported by the provided FDA label excerpts.
Rinvoq treatment leads to less itching in patients with atopic dermatitis.
Not supported by the provided FDA label excerpts.
In clinical trials, 36-70% of patients achieved clear or almost clear skin after 16 weeks on 15 mg or 30 mg daily doses.
Not supported by provided label excerpts.
In clinical trials, 8-13% of patients achieved clear or almost clear skin after 16 weeks on placebo.
Not supported by provided label excerpts.
Itch relief with Rinvoq often starts within the first week.
Not supported by provided label excerpts.
Rinvoq is an oral JAK inhibitor.
Not supported by provided label excerpts.
Rinvoq works faster on itch than dupilumab (Dupixent), an injectable IL-4/IL-13 blocker.
Not supported by provided label excerpts (also involves comparative timing and a dupilumab claim).
Both Rinvoq and Dupixent carry black box warnings for serious infections.
Dupixent labeling is not included in the supplied label excerpts; the provided Rinvoq excerpts do not explicitly mention 'black box' wording.
Both Rinvoq and Dupixent carry black box warnings for heart issues.
Dupixent labeling not provided; also the provided Rinvoq excerpts describe MACE risk without explicitly stating 'black box' wording.
Both Rinvoq and Dupixent carry black box warnings for cancer risk.
Dupixent labeling not provided; provided Rinvoq excerpts describe malignancy risk without explicitly stating 'black box' wording.
Upper respiratory infections occur in 20-30% of patients receiving Rinvoq.
Not supported by provided label excerpts (6.1 excerpt provides serious infections counts, not URTI incidence ranges).
Acne occurs in 10-20% of patients receiving Rinvoq.
Not supported by provided label excerpts.
Nausea occurs in 5-10% of patients receiving Rinvoq.
Not supported by provided label excerpts.
Herpes zoster occurs in 3-5% of patients receiving Rinvoq.
Not supported by provided label excerpts (no incidence range for herpes zoster is provided in the supplied text).
Long-term use of Rinvoq raises infection risk.
Not supported by provided label excerpts.
Long-term use of Rinvoq raises blood clot risk.
Not supported by provided label excerpts.
Rinvoq is prescribed after failing topical treatments or phototherapy.
Not supported by provided label excerpts.
Rinvoq is not for mild eczema.
Not supported by provided label excerpts.
Rinvoq is not first-line use for eczema.
Not supported by provided label excerpts.
Hepatitis screening is required before starting Rinvoq.
Not supported as a 'required' pre-treatment screening statement in the provided excerpts; the excerpt states screening/monitoring should be performed in accordance with clinical guidelines.
The standard Rinvoq dosage for atopic dermatitis is 15 mg once daily.
Not supported by provided label excerpts.
Rinvoq dosage can be increased to 30 mg once daily for inadequate response.
Not supported by provided label excerpts.
The annual U.S. cost of Rinvoq exceeds $70,000 without insurance.
Not supported by provided label excerpts.
Patient assistance programs can reduce Rinvoq cost to $5-25 per month for eligible users.
Not supported by provided label excerpts.
AbbVie's key U.S. patents on Rinvoq expire in 2033.
Not supported by provided label excerpts.
Pediatric extensions for Rinvoq patents are possible to 2037.
Not supported by provided label excerpts.
No generics for Rinvoq are expected until those patent expirations.
Not supported by provided label excerpts.
Rinvoq has ongoing generic-related challenges.
Not supported by provided label excerpts.
The annual U.S. cost ...
Not supported by provided label excerpts.
Contradictions
Low
AI Statement
Hepatitis screening is required before starting Rinvoq.
Label Reference
Label excerpt 5.1 states: 'Screening for viral hepatitis and monitoring for reactivation should be performed in accordance with clinical guidelines before starting and during therapy,' which does not state 'required' as an absolute requirement.
Important Omissions
For infection-risk counseling, the label excerpt includes specific operational guidance (avoid use in active serious infection; interruption if serious/opportunistic infection; prompt diagnostic testing; may resume once infection controlled). If the AI response discussed infection risk, it should align with these management steps from 5.1.
Importance:
Moderate
Mortality/CV risk guidance from 5.2/5.4 includes considering benefits/risks and patient symptom counseling; the provided AI claims about 'black box warnings' for heart issues do not reflect these specific label management instructions.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several efficacy and dosing/administration claims are not supported by the supplied label excerpts, and multiple adverse event incidence range claims (URIs, acne, nausea, herpes zoster) are unsupported. However, core safety risk categories (serious infections/opportunistic infections, mortality, malignancy, MACE, thrombosis) are supported by the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Many claims (indication/dosing/efficacy outcomes and multiple adverse event incidence percentages, live vaccine avoidance, and cost/patent assertions) are not supported by the provided label excerpts; 'black box' wording for dupilumab and specific risk framing is also not supported.
Suggested Improvement
Limit statements to what is supported by the provided label excerpts (Sections 5.1–5.5 and 6.1) or supply the missing label sections (e.g., Indications/Dosing, clinical trial results, adverse reactions, vaccine guidance, boxed warning wording, and dupilumab labeling) before making those claims.